Table 3.
| A)Estimated pharmacokinetic parameters of raltegravir, etravirine and darunavir | |||
|---|---|---|---|
| Raltegravir (RSE)* | Etravirine (RSE)* | Darunavir (RSE)* | |
| Number of transition compartments | 2 | 4 | 2 |
| Mean absorption time (h) | 1.49 (27.9%) | 1.77 (14.8%) | 0.965 (22.3%) |
| CL/F (l h−1) | 191 (16.0%) | 55.3 (9.11%) | 21.3 (13.9%) |
| V/F (l) | 820 (25.5%) | 781 (13.6%) | 220 (14.5%) |
| Accumulation ratio | – | 12.9 (16.3%) | 1.32 (12.3%) |
| IIV MAT (%) | 75.0 (59.5%) | 36.9 (14.8%) | 62.8 (22.3%) |
| IIV CL/F (%) | 49.7 (59.5%) | 26.3 (23.2%) | 43.0 (31.1%) |
| Correlation IIV CL/F and IIV V/F | 0.273 (47.6%) | 0.0697 (45.2%) | 0.133 (37.5%) |
| IIV V/F (%) | 72.1 (35.6%) | 30.3 (60.3%) | 40.5 (38.2%) |
| IIV accumulation ratio (%) | – | 55.1 (52.4%) | 35.4 (52.7%) |
| Exponential residual error plasma observations (%) | 68.1 | 13.2 | 19.4 |
| Exponential residual error intracellular observations (%) | – | 53.3 | 75.2 |
| B)Estimated pharmacokinetic parameters of ritonavir | |||
| Ritonavir (RSE)* | |||
| Absorption lag time (h) | 0.778 | ||
| Ka (h−1) | 0.871 | ||
| CL/F (l h−1) | 10.5 | ||
| V/F (l) | 96.6 | ||
| Relative bioavailability (%) | 20.3 (20.1%) | ||
| Accumulation ratio | 7.72 (13.0%) | ||
| IIV Ka (%) | 160 (20.9%) | ||
| IIV CL/F (%) | 37.8 (20.8%) | ||
| IIV V/F (%) | 48.5 (36.2%) | ||
| Correlation IIV V/F and IIV Ka | 0.426 (29.3%) | ||
| IIV accumulation ratio (%) | 40.7 (77.5%) | ||
| Proportional error plasma observations (%) | 19.5 (20.7%) | ||
| Additive error plasma observations (mg l−1) | 0.0236 (53.8%) | ||
| IIV additive error plasma observations (%) | 105 (106%) | ||
| Exponential error intracellular observations (%) | 37.7 (14.9%) | ||
*
RSE, Relative Standard Error of estimate.